Position
Navalign, LLC in Allogene Therapeutics, Inc.
Back to the book · All holders of ALLO
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $52.9K$1.37 → $2.44
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 49.4K | $67.7K | — | — | — | 0.0% |
| Q1 2026 | 49.4K | $120.5K | $2.44 | $52.9K | −$0 | 0.0% |